International Agency for Research on Cancer (IARC) - Summaries & Evaluations


VOL.: 26 (1981) (p. 237)

CAS No.: 3778-73-2
Chem. Abstr. Name: 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)-tetrahydro-, 2-oxide

5. Summary of Data Reported and Evaluation

5.1 Experimental data

Isophosphamide was tested in four studies in mice and in one in rats by subcutaneous or intraperitoneal administration. In one study in mice with intraperitoneal injection it produced an increased incidence of lung adenomas. The other four studies, although indicating a carcinogenic effect, could not be evaluated.

Isophosphamide can induce teratogenic effects in mice and embryolethality at doses nontoxic to the mother. Isophosphamide is mutagenic in bacteria and produced chromosomal aberrations in Chinese hamster bone-marrow cells.

5.2 Human data

Isophosphamide has been used to a limited but increasing extent since the early 1970s as an antineoplastic and immunosuppressive drug.

No data were available to evaluate the teratogenic or mutagenic potential or chromosomal effects of isophosphamide in humans.

No case report or epidemiological study on isophosphamide was available to the Working Group.

5.3 Evaluation

There is limited evidence for the carcinogenicity of isophosphamide in mice and rats.

In the absence of data on humans, no evaluation can be made of the carcinogenic risk of isophosphamide to man.

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Suppl. 7 (1987) (p. 65: Group 3)

Synonyms for Isophosphamide

Last updated: 8 April 1998

    See Also:
       Toxicological Abbreviations